Clinical Trials Logo

Lung Neoplasms clinical trials

View clinical trials related to Lung Neoplasms.

Filter by:

NCT ID: NCT02470065 Suspended - Clinical trials for Non Small Cell Lung Cancer

Neoadjuvant Afatinib in Early Stage Non Small Cell Lung Cancer.

REMNANT
Start date: January 2016
Phase: Phase 2
Study type: Interventional

This is a multicenter, randomized, 1:1, non-comparative phase II trial. Patients with early stage NSCLC will be randomized between ARM A: neoadjuvant afatinib followed by surgery and ARM B: immediate surgery with curative intent.

NCT ID: NCT02356991 Suspended - Clinical trials for Non-Small Cell Lung Cancer (NSCLC)

A Study of Famitinib in Patients With Advanced Non-squamous and Non-Small Cell Lung Cancer (NSCLC)

Start date: December 2014
Phase: Phase 2
Study type: Interventional

Famitinib is a tyrosin-inhibitor agent targeting at c-Kit, VEGFR2, PDGFR, VEGFR3, Flt1 and Flt3. Phase I study has shown that the toxicity is manageable. The purpose of this study is to evaluate the efficacy and safety profile of Famitinib in patients with Advanced Non-squamous and Non-Small Cell Lung Cancer (NSCLC).

NCT ID: NCT01720901 Suspended - Clinical trials for Non-small Cell Lung Cancer

Increased Dose of Icotinib in Advanced None Small Cell Lung Cancer Patients After Routine Gefitinib Therapy

Start date: February 2013
Phase: Phase 4
Study type: Interventional

To evaluate the efficacy and safety of increased dose of icotinib in advanced NSCLC patients who progressed after gefitinib therapy.

NCT ID: NCT01627795 Suspended - Mesothelioma Clinical Trials

Safety and Efficacy of Oshadi D and Oshadi R for Malignant Mesothelioma Treatment

Start date: December 2016
Phase: Phase 1/Phase 2
Study type: Interventional

Malignant mesothelioma is a rare neoplasm that arises most commonly from the mesothelial surfaces of the pleural cavity, occasionally from the peritoneal surface, and rarely from the tunica vaginalis or pericardium. It has an extremely poor prognosis with a median survival of 4 to 13 months for untreated patients 1 and 6 to 18 months for treated patients, regardless of the therapeutic approach. The anticancer activity of Oshadi D and Oshadi R treatment was tested in preclinical studies and in phase I clinical study. Four metastatic mesothelioma patients are treated for 5 to 12 months. The Oshadi D and Oshadi R combination treatment was generally well-tolerated with no dose-limiting toxicities observed.

NCT ID: NCT01356303 Suspended - Clinical trials for Non-small Cell Lung Cancer Metastatic

Docetaxel Combined With Cisplatin as First Line in Patients With Metastatic Non-small Cell Lung Cancer

TAXIS01
Start date: March 2009
Phase: Phase 2
Study type: Interventional

This is a phase II, open-label clinical study prospectively enrolling 40 metastatic patients with non small cell lung cancer. The study will enroll patients at King Abdulaziz Medical City, Riyadh. Sub-sites will be open for patient accrual in selected centers in the Kingdom.

NCT ID: NCT01320501 Suspended - Clinical trials for Non-small Cell Lung Cancer Metastatic

Experience of Erlotinib in Patients With Advanced Non-Small Cell Lung Cancer

REALME
Start date: October 2009
Phase: Phase 4
Study type: Interventional

An open-label, prospective, single-arm, multi-center phase IV clinical trial of TarcevaTM as single agent

NCT ID: NCT00986284 Suspended - Clinical trials for Non Small Cell Lung Cancer

Epidermal Growth Factor Receptor (EGFR) Status Based Gefitinib Neoadjuvant Therapy in Non Small Cell Lung Cancer (NSCLC)

Start date: September 2009
Phase: Phase 2
Study type: Interventional

This study aims to investigate the efficacy and safety of gefitinib as neoadjuvant therapy in stage IIIA NSCLC patients.

NCT ID: NCT00280189 Suspended - NSCLC Clinical Trials

Study of Outcomes of Radiofrequency Ablation of Lung Tumors

Start date: September 2003
Phase:
Study type: Observational

The purpose of this study is to assess short and long term outcomes after radiofrequency ablation (RFA) of pulmonary malignancies in patients who are not candidates for surgical resection. This study will evaluate the efficacy of RFA for the treatment of lung tumors by assessing its impact on local tumor control, progression free survival, overall survival, dyspnea score and quality of life (QOL).